全文获取类型
收费全文 | 38510篇 |
免费 | 2093篇 |
国内免费 | 108篇 |
专业分类
耳鼻咽喉 | 602篇 |
儿科学 | 1636篇 |
妇产科学 | 633篇 |
基础医学 | 4999篇 |
口腔科学 | 944篇 |
临床医学 | 2447篇 |
内科学 | 9439篇 |
皮肤病学 | 1312篇 |
神经病学 | 3211篇 |
特种医学 | 1049篇 |
外科学 | 5338篇 |
综合类 | 231篇 |
一般理论 | 17篇 |
预防医学 | 3315篇 |
眼科学 | 1120篇 |
药学 | 2296篇 |
中国医学 | 177篇 |
肿瘤学 | 1945篇 |
出版年
2024年 | 40篇 |
2023年 | 285篇 |
2022年 | 189篇 |
2021年 | 977篇 |
2020年 | 453篇 |
2019年 | 1104篇 |
2018年 | 1823篇 |
2017年 | 1057篇 |
2016年 | 865篇 |
2015年 | 707篇 |
2014年 | 831篇 |
2013年 | 1576篇 |
2012年 | 2860篇 |
2011年 | 3283篇 |
2010年 | 1517篇 |
2009年 | 848篇 |
2008年 | 2570篇 |
2007年 | 2645篇 |
2006年 | 2388篇 |
2005年 | 2457篇 |
2004年 | 2268篇 |
2003年 | 2210篇 |
2002年 | 1990篇 |
2001年 | 1376篇 |
2000年 | 1827篇 |
1999年 | 901篇 |
1998年 | 233篇 |
1997年 | 154篇 |
1996年 | 150篇 |
1995年 | 120篇 |
1994年 | 96篇 |
1993年 | 84篇 |
1992年 | 70篇 |
1991年 | 47篇 |
1990年 | 47篇 |
1989年 | 53篇 |
1988年 | 62篇 |
1987年 | 40篇 |
1986年 | 42篇 |
1985年 | 68篇 |
1984年 | 49篇 |
1983年 | 44篇 |
1982年 | 48篇 |
1981年 | 34篇 |
1980年 | 35篇 |
1978年 | 31篇 |
1977年 | 23篇 |
1976年 | 20篇 |
1975年 | 24篇 |
1973年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
991.
992.
Ana Marcos-Jiménez Santiago Sánchez-Alonso Ana Alcaraz-Serna Laura Esparcia Celia López-Sanz Miguel Sampedro-Núñez Tamara Mateu-Albero Ildefonso Sánchez-Cerrillo Pedro Martínez-Fleta Ligia Gabrie Luciana del Campo Guerola José Miguel Rodríguez-Frade José M. Casasnovas Hugh T. Reyburn Mar Valés-Gómez Margarita López-Trascasa Enrique Martín-Gayo María José Calzada Santos Castañeda Hortensia de la Fuente Isidoro González-Álvaro Francisco Sánchez-Madrid Cecilia Muñoz-Calleja Arantzazu Alfranca 《European journal of immunology》2021,51(3):634-647
SARS-CoV-2 infection causes an abrupt response by the host immune system, which is largely responsible for the outcome of COVID-19. We investigated whether the specific immune responses in the peripheral blood of 276 patients were associated with the severity and progression of COVID-19. At admission, dramatic lymphopenia of T, B, and NK cells is associated with severity. Conversely, the proportion of B cells, plasmablasts, circulating follicular helper T cells (cTfh) and CD56–CD16+ NK-cells increased. Regarding humoral immunity, levels of IgM, IgA, and IgG were unaffected, but when degrees of severity were considered, IgG was lower in severe patients. Compared to healthy donors, complement C3 and C4 protein levels were higher in mild and moderate, but not in severe patients, while the activation peptide of C5 (C5a) increased from the admission in every patient, regardless of their severity. Moreover, total IgG, the IgG1 and IgG3 isotypes, and C4 decreased from day 0 to day 10 in patients who were hospitalized for more than two weeks, but not in patients who were discharged earlier. Our study provides important clues to understand the immune response observed in COVID-19 patients, associating severity with an imbalanced humoral response, and identifying new targets for therapeutic intervention. 相似文献
993.
994.
Cristobalina Mayorga Ezequiel Perez-Inestrosa Javier Rojo Marta Ferrer Maria Isabel Montañez 《Allergy》2021,76(11):3292-3306
Nanotechnology is science, engineering and technology conducted at the nanoscale, which is about 1–100 nm. It has led to the development of nanomaterials, which behave very differently from materials with larger scales and can have a wide range of applications in biomedicine. The physical and chemical properties of materials of such small compounds depend mainly on the size, shape, composition and functionalization of the system. Nanoparticles, carbon nanotubes, liposomes, polymers, dendrimers and nanogels, among others, can be nanoengineeried for controlling all parameters, including their functionalization with ligands, which provide the desired interaction with the immunological system, that is dendritic cell receptors to activate and/or modulate the response, as well as specific IgE, or effector cell receptors. However, undesired issues related to toxicity and hypersensitivity responses can also happen and would need evaluation. There are wide panels of accessible structures, and controlling their physico-chemical properties would permit obtaining safer and more efficient compounds for clinical applications goals, either in diagnosis or treatment. The application of dendrimeric antigens, nanoallergens and nanoparticles in allergy diagnosis is very promising since it can improve sensitivity by increasing specific IgE binding, mimicking carrier proteins or enhancing signal detection. Additionally, in the case of immunotherapy, glycodendrimers, liposomes, polymers and nanoparticles have shown interest, behaving as platforms of allergenic structures, adjuvants or protectors of allergen from degradation or having a depot capacity. Taken together, the application of nanotechnology to allergy shows promising facts facing important goals related to the improvement of diagnosis as well as specific immunotherapy. 相似文献
995.
Teodorikez-Wilfox Jimenez-Rodriguez María Pilar Berges-Gimeno Ruth Barranco Joan Bartra María del Carmen Diéguez Inmaculada Doña Montserrat Fernández-Rivas Maria Del Mar Gandolfo-Cano Gabriel Gastaminza-Lasarte Eloína González-Mancebo Belén de la Hoz Caballer Leticia Sánchez-Morillas María José Torres Arantza Vega Rosa Muñoz-Cano 《Allergy》2021,76(7):2249-2253
996.
Castano-Jaramillo Lina M. Yamazaki-Nakashimada Marco Antonio O’Farrill-Romanillos Patricia M. Muzquiz Zermeño David Scheffler Mendoza Selma C. Venegas Montoya Edna García Campos Jorge Alberto Sánchez-Sánchez Luz María Gámez González Luisa B. Ramírez López Jesús Moisés Bustamante Ogando Juan Carlos Vásquez-Echeverri Estefanía Medina Torres Edgar Alejandro Lopez-Herrera Gabriela Blancas Galicia Lizbeth Berrón Ruiz Laura Staines-Boone Aidé Tamara Espinosa-Padilla Sara Elva Segura Mendez Nora Hilda Lugo Reyes Saul O. 《Journal of clinical immunology》2021,41(7):1463-1478
Journal of Clinical Immunology - Patients with inborn errors of immunity (IEI) have a compromised or inappropriate immune response. Although they might be considered a high-risk group for severe... 相似文献
997.
José H. Marco Isabel Fernandez-Felipe Sara Fonseca Azucena Garcia-Palacios Rosa Baños Verónica Guillen 《Clinical psychology & psychotherapy》2021,28(6):1598-1606
Emotional dysregulation is a key symptom in participants with personality disorders. The Emotional Regulation Questionnaire (ERQ) has been studied with nonclinical samples; however, it is necessary to confirm the factorial structure of the ERQ in participants with personality disorders. The aims of the present study were to confirm the factorial structure of the Spanish version of the ERQ and analyse its psychometric properties as well as the association between the ERQ and the Borderline Symptoms List (BSL-23) and the Difficulties in Emotion Regulation Scale (DERS). The overall sample was composed of 250 patients with personality disorders, of whom 195 met the criteria for borderline personality disorder. Confirmatory factor analysis was conducted. The two-factor model showed an acceptable fit, similar to the original structure, in the participants with personality disorders and with borderline personality disorder. Cognitive reappraisal was negatively correlated with the DERS and BSL-23, and expressive suppression was positively correlated with the BSL-23. The ERQ is a reliable and valid instrument to evaluate emotional dysregulation in participants with personality disorders and participants with borderline personality disorder. 相似文献
998.
P.M. Martínez Pérez-Crespo L.E. López-Cortés P. Retamar-Gentil J.F. Lanz García D. Vinuesa García E. León J.M. Sánchez Calvo F. Galán-Sánchez C. Natera Kindelan A. del Arco Jiménez A. Sánchez-Porto C. Herrero Rodríguez B. Becerril Carral I.M. Reche Molina J.M. Reguera Iglesias I. Pérez Camacho M. Guzman García I. López-Hernández J. Rodríguez-Baño 《Clinical microbiology and infection》2021,27(2):283.e9-283.e16
ObjectivesDuring the last decade, some changes in the epidemiology of invasive infections have been reported; however, specific studies with patient-level data are scarce. The aim of this study was to describe and evaluate the epidemiologic changes in bloodstream infections (BSI) during the last decade in Andalucía, Spain.MethodsData from two prospective cohorts of BSI in adults with the same methodology performed 10 years apart in 11 hospitals (eight tertiary and three community) in Andalucía, Spain, were compared; the 2006–7 cohort study was performed between October 2006 and March 2007, and the 2016–17 cohort study was performed between October 2016 and March 2017. Population-based incidence rates were calculated and extrapolated for 1 year. Relative risk ratios were calculated between the 2 periods. Multivariate analyses were performed by logistic regression.ResultsOverall, 1262 episodes of BSI were included, 563 (44.6%) in 2006–7 and 699 (55.3%) in 2016–17. Multivariate models selected the following changes in patients' features in 2016–17, after controlling for type of acquisition: higher age (odds ratio (OR) = 1.02; 95% confidence interval [CI] 1.01–1.03), lower urinary catheter (OR = 0.37; 95% CI, 0.26–0.48) and lower Pitt score (OR = 0.76; 95% CI, 0.71–0.82). Adjusted estimations considering patients' features and exposure to procedures showed a reduction in coagulase-negative staphylococci (OR = 0.47; 95% CI, 0.32–0.69), and an increase in Proteus spp. (OR = 3.12; 95% CI, 1.18–8.23) and Candida spp. (OR = 3.01; 95% CI, 1.03–8.86).ConclusionsWe found relevant epidemiologic changes in BSI in our area, including rates, frequency of acquisition types, changes in patient's profiles and aetiologic agents. 相似文献
999.
Jesús Rodríguez-Baño Jerónimo Pachón Jordi Carratalà Pablo Ryan Inmaculada Jarrín María Yllescas José Ramón Arribas Juan Berenguer 《Clinical microbiology and infection》2021,27(2):244-252
ObjectivesThe objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters.MethodsA cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs).ResultsIn all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22–0.47; p < 0.001) for tocilizumab, 0.82 (0.71–1.30; p 0.82) for IHDC, 0.61 (0.43–0.86; p 0.006) for PDC, and 1.17 (0.86–1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02–0.17; p < 0.001).ConclusionsTocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situation. 相似文献
1000.
Aina Mesquida Teresa Vicente Elena Reigadas María Palomo Carlos Sánchez-Carrillo Patricia Muñoz Jesús Guinea Pilar Escribano 《Clinical microbiology and infection》2021,27(6):915.e5-915.e8
ObjectivesEmergence of azole resistance may contribute to recurrences of vulvovaginal candidiasis. Thus, new drugs are needed to improve the therapeutic options. We studied the in vitro activity of ibrexafungerp and comparators against Candida albicans isolates from vaginal samples and blood cultures. Furthermore, isolates were genotyped to study compartmentalization of genotypes and the relationship between genotype and antifungal susceptibility.MethodsCandida albicans unique patient isolates (n = 144) from patients with clinical suspicion of vulvovaginal candidiasis (n = 72 isolates) and from patients with candidaemia (n = 72) were studied. Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, posaconazole, isavuconazole, clotrimazole, miconazole, micafungin, anidulafungin and ibrexafungerp was tested (EUCAST 7.3.2). Mutations in the erg11 gene were analysed and isolates genotyped.ResultsIbrexafungerp showed high activity (MICs from 0.03 mg/L to 0.25 mg/L) against the isolates, including those with reduced azole susceptibility, and regardless of their clinical source. Fluconazole resistance rate was 7% (n = 5/72) and 1.4% (n = 1/72) in vaginal and blood isolates, respectively. Some amino acid substitutions in the Erg11 protein were observed exclusively in phenotypically fluconazole non-wild type. Population structure analysis suggested two genotype populations, one mostly involving isolates from blood samples (66.3%) and the mostly from vaginal samples (69.8%). The latter group hosted all fluconazole non-wild-type isolates.DiscussionIbrexafungerp shows good in vitro activity against Candida albicans from vaginal samples including phenotypically fluconazole non-wild-type isolates. Furthermore, we found a certain population structure where some genotypes show reduced susceptibility to fluconazole. 相似文献